{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:40:59Z","timestamp":1784590859508,"version":"3.55.0"},"reference-count":36,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Anal squamous cell carcinoma (ASCC) is a rare malignancy with an increasing incidence despite advancements in treatment. The primary treatment for localized ASCC is radiochemotherapy (RCT), which achieves high rates of tumor regression in most cases, but up to 30% of patients experience recurrence or persistent disease. Salvage surgery, such as an abdominoperineal resection (APR), is often used for recurrent disease but is associated with significant morbidity and limited oncological outcomes. Patients with small T1 tumors may also benefit from primary local excision. For patients with metastatic or unresectable recurrent ASCC, chemotherapy, particularly carboplatin and paclitaxel, remains the standard treatment. New therapeutic strategies, including immune checkpoint inhibitors like pembrolizumab, are showing promise, particularly in PD-L1-positive tumors. Clinical trials have suggested that immunotherapy offers a potential alternative for patients for whom conventional treatments have failed, though the overall response rates remain modest. Re-radiation and intraoperative radiotherapy combined with salvage surgery may improve the outcomes for select patients, though the data are still limited. The management of recurrent or persistent ASCC requires a personalized approach, incorporating both established and emerging therapies to optimize patient outcomes. Further research is needed to refine these treatment strategies.<\/jats:p>","DOI":"10.3390\/cancers17091511","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:05:57Z","timestamp":1745989557000},"page":"1511","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Squamous Cell Carcinomas of the Anal Canal and Anal Margin After Failure of Chemoradiotherapy Treatment: A Narrative Review"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-6561","authenticated-orcid":false,"given":"Micha\u00ebl","family":"Racine","sequence":"first","affiliation":[{"name":"Visceral Surgery, Department of Surgery, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Meurette","sequence":"additional","affiliation":[{"name":"Visceral Surgery, Department of Surgery, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-6101","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Ris","sequence":"additional","affiliation":[{"name":"Visceral Surgery, Department of Surgery, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Meyer","sequence":"additional","affiliation":[{"name":"Visceral Surgery, Department of Surgery, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1652-4522","authenticated-orcid":false,"given":"Christian","family":"Toso","sequence":"additional","affiliation":[{"name":"Visceral Surgery, Department of Surgery, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Liot","sequence":"additional","affiliation":[{"name":"Visceral Surgery, Department of Surgery, Geneva University Hospital, 1205 Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/curroncol30030246","article-title":"Anal Cancer: The Past, Present and Future","volume":"30","author":"Gondal","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: A systematic review and meta-analysis","volume":"18","author":"Lin","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year followup of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs. fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"UKCCCR Anal Cancer Trial Working Party (1996). Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet, 348, 1049\u20131054.","DOI":"10.1016\/S0140-6736(96)03409-5"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/codi.14569","article-title":"A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer","volume":"21","author":"Ko","year":"2019","journal-title":"Color. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"106929","DOI":"10.1016\/j.ejso.2023.05.004","article-title":"Survival outcomes following salvage abdominoperineal resection for recurrent and persistent anal squamous cell carcinoma","volume":"49","author":"Kitaguchi","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Xiao, W., Yuan, Y., Wang, S., Liao, Z., Cai, P., Chen, B., Zhang, R., Wang, F., Zeng, Z., and Gao, Y. (2022). Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.798451"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Upadhyay, L., Hartzell, M., Parikh, A.R., Strickland, M.R., Klempner, S., and Malla, M. (2023). Recent Advances in the Management of Anal Cancer. Healthcare, 11.","DOI":"10.3390\/healthcare11233010"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.ejso.2018.06.016","article-title":"30-day and long-term outcome following salvage surgery for squamous cell carcinoma of the anus","volume":"44","author":"Pedersen","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1259\/bjr\/96187638","article-title":"Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation","volume":"81","author":"Koh","year":"2008","journal-title":"Br. J. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ejso.2019.01.181","article-title":"Quality of life following salvage surgery for squamous cell carcinoma of the anus","volume":"45","author":"Pedersen","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/codi.12306","article-title":"Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca\u2014A single institution\u2019s experience over 16 years","volume":"15","author":"Tan","year":"2013","journal-title":"Color. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s11845-024-03651-3","article-title":"Primary closure versus vertical rectus abdominis myocutaneous (VRAM) flap closure of perineal wound following abdominoperineal resection-a systematic review and meta-analysis","volume":"193","author":"Temperley","year":"2024","journal-title":"Ir. J. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SLA.0b013e3181bce334","article-title":"Abdomino-perineal resection for anal cancer: Impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing","volume":"250","author":"Lefevre","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rosen, R., Quezada-Diaz, F.F., G\u00f6nen, M., Karagkounis, G., Widmar, M., Wei, I.H., Smith, J.J., Nash, G.M., Weiser, M.R., and Paty, P.B. (2024). Oncologic Outcomes of Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma Initially Managed with Chemoradiation. J. Clin. Med., 13.","DOI":"10.3390\/jcm13082156"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1245\/s10434-018-6483-9","article-title":"Salvage Abdominoperineal Resection for Squamous Cell Anal Cancer: A 30-Year Single-Institution Experience","volume":"25","author":"Hagemans","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jso.25489","article-title":"Early versus late salvage abdominoperineal resection for anal squamous cell carcinoma: Is there a difference in survival?","volume":"120","author":"Fields","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jss.2020.05.034","article-title":"Inguinal Lymph Node Dissection Does Not Improve Overall Survival in Anal Cancer Nodal Disease","volume":"255","author":"Lin","year":"2020","journal-title":"J. Surg. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): A multicentre, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clcc.2023.12.002","article-title":"Salvage Treatment of Recurrent or Persistent Anal Squamous Cell Carcinoma: The Role of Multi-modality Therapy","volume":"23","author":"Damron","year":"2024","journal-title":"Clin. Color. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/DCR.0000000000000071","article-title":"Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy","volume":"57","author":"Hallemeier","year":"2014","journal-title":"Dis. Colon. Rectum."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21037\/jgo.2019.04.03","article-title":"Proton beam radiotherapy for anal and rectal cancers","volume":"11","author":"Vaios","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(24)00081-0","article-title":"Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): A randomised, non-comparative, phase 2 study","volume":"25","author":"Kim","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jiang, X., Ji, Z., Lei, X., He, Y., and Yuan, F. (2023). Cryotherapy for low rectal and anal cancer: Recommendation and indications. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.984145"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1511\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:37Z","timestamp":1760030677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091511"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091511","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}